Uniphar plc

Uniphar plc

UPR.IR
Uniphar plcundefined flagEuronext Dublin
4.80
EUR
+0.02
- -
1.25BMarket Cap
Uniphar plc
UPR.IR
(Euronext Dublin)

Recent

price

4.80

P/E

ratio

- -

div

yld

- -

ROIC.AI

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
4.82
4.71
11.91
9.07
6.95
7.2
7.6
9.35
10.15
- -
Revenue per Share
0.02
- -
0.07
0.11
0.11
0.18
0.17
0.16
0.24
- -
Basic EPS, GAAP
0.05
-0.02
-0.11
0.55
0.19
0.14
0.23
0.08
0.08
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
0.01
0.02
0.02
0.02
0.02
- -
Dividend per Share
-0.12
-0.12
-0.19
0.01
0.1
0.26
0.4
0.55
0.77
- -
Book Value per Share
-0.27
-0.32
-1.74
-0.53
-0.68
-0.72
-0.8
-0.84
-0.61
- -
Tangible Book Value per Share
269
269
119
184
262
270
273
273
273
- -
Basic Weighted Avg Shares
1,296
1,267
1,418
1,665
1,824
1,943
2,071
2,553
2,770
3,075
Sales/Revenue/Turnover
1.32
0.86
1.73
2.41
2.56
3.06
3.36
3.05
3.07
2.97
Operating Margin (%)
6
7
7
18
20
27
28
35
35
36
Depreciation Expense
6
-1
9
21
28
48
46
45
64
51
Net Income, GAAP
21.53
- -
22.99
20.93
17.06
13.76
16.41
14.65
15.03
18.77
Effective Tax Rate (%)
0.44
-0.08
0.61
1.26
1.53
2.47
2.2
1.76
2.32
1.66
Profit Margin (%)
-68
-84
-77
9
-42
-30
-41
-66
-77
-6
Working Capital
20
12
84
150
203
229
293
349
374
490
LT Debt
-10
-11
-1
181
203
252
290
334
402
405
Total Equity
- -
- -
17.09
11.69
9.6
10.89
10.27
9.73
9.28
8.46
Return on Invested Capital (%)
- -
- -
14.12
16.92
16.06
19.27
14.86
13.66
15
10.11
Return on Capital (%)
- -
- -
- -
- -
196.66
99.69
50.73
34.42
35.62
23.7
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
15.16%
0.82%
Free Cash Flow
- -
17.6%
105.65%
Net Income, GAAP
- -
17.75%
-20.43%
Sales/Revenue/Turnover
- -
11.18%
10.98%
Total Cash Common Dividend
- -
35.55%
0.14%

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
2,553
2024
- -
- -
- -
- -
2,770
2025
- -
- -
- -
- -
3,075

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.16
2024
- -
- -
- -
- -
0.24
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.02
2024
- -
- -
- -
- -
0.02
2025
- -
- -
- -
- -
- -
Business
Uniphar plc operates as a diversified healthcare services provider focused on pharmaceutical distribution, medical devices, and specialized pharma support services. The company, founded in 1967 and headquartered in Dublin, Ireland, delivers its offerings through three primary divisions: Uniphar Medtech, which provides sales, marketing, compliance, and distribution services to medical device manufacturers across specialties including interventional cardiology, radiology, orthopaedics, ophthalmology, minimally invasive surgery, diagnostic imaging, and critical care; Uniphar Pharma, which supplies high-value services across the pharmaceutical product lifecycle such as global sourcing of unlicensed and hard-to-access medicines, managed access programs, medical affairs, clinical development, and product fostering for over 200 multinational pharma and biotech clients in more than 160 countries; and Uniphar Supply Chain & Retail, which handles pre-wholesale and wholesale distribution of pharmaceuticals, healthcare, and animal health products to pharmacies, hospitals, and veterinary surgeons, alongside operating a network of retail pharmacies under the Life, Allcare, Hickey’s, and McCauley brands. Uniphar serves public and private sector customers primarily in Ireland, the United Kingdom, the Netherlands, the United States, Europe, APAC, and MENA regions, with approximately 3,500 employees and annual revenue exceeding €2 billion. Recent developments include a major U.S. expansion announced in November 2025, integrating RRD BioPharma Development, Uniphar Clinical, Diligent Health Solutions, and BESTMSLs under the Uniphar brand, complemented by the opening of a new 65,000 sq. ft. GMP- and GDP-compliant facility in Raleigh, North Carolina; the acquisition of Inspired Health, Inc. from West Monroe Partners in December 2024 with integration set for the first half of 2025; a strategic partnership with Secura Bio for global Managed Access Programs covering products like Farydak and Copiktra; and a rebranding of its On Demand business to Uniphar Global Sourcing in July 2025 to bolster its pharmaceutical offerings.